Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy F Cobbold

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Gastroenterology|January 29, 2019
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver DiseasePeter J Eddowes, Magali Sasso, Michael Allison, et al.
Gut Microbes|September 28, 2024
Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosisDimitrios A Koutoukidis, Sandi Yen, Paula Gomez Castro, et al.
JHEP Reports : Innovation in Hepatology|September 30, 2020
Systemic iron reduction by venesection alters the gut microbiome in patients with haemochromatosisBhavika Parmanand, Michael Watson, Karen J Boland, et al.
JHEP Reports : Innovation in Hepatology|May 9, 2025
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLDAhmad Moolla, Toryn Poolman, Nantia Othonos, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 6, 2017
Hepatic iron is the major determinant of serum ferritin in NAFLD patientsJohn D Ryan, Andrew E Armitage, Jeremy F Cobbold, et al.
BMJ Open|January 18, 2024
Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation studyHamish Miller, David Harman, Guruprasad Padur Aithal, et al.
Diabetes Research and Clinical Practice|August 15, 2024
Glycated haemoglobin is a major predictor of disease severity in patients with NAFLDSanto Colosimo, Hamish Miller, Dimitrios A Koutoukidis, et al.
JHEP Reports : Innovation in Hepatology|January 24, 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevanceKatherine Johnson, Peter J Leary, Olivier Govaere, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2020
Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolomeAhmad Moolla, Jasper de Boer, David Pavlov, et al.
Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Gastroenterology|January 29, 2019
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver DiseasePeter J Eddowes, Magali Sasso, Michael Allison, et al.
Gut Microbes|September 28, 2024
Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosisDimitrios A Koutoukidis, Sandi Yen, Paula Gomez Castro, et al.
JHEP Reports : Innovation in Hepatology|September 30, 2020
Systemic iron reduction by venesection alters the gut microbiome in patients with haemochromatosisBhavika Parmanand, Michael Watson, Karen J Boland, et al.
JHEP Reports : Innovation in Hepatology|May 9, 2025
Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLDAhmad Moolla, Toryn Poolman, Nantia Othonos, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 6, 2017
Hepatic iron is the major determinant of serum ferritin in NAFLD patientsJohn D Ryan, Andrew E Armitage, Jeremy F Cobbold, et al.
BMJ Open|January 18, 2024
Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation studyHamish Miller, David Harman, Guruprasad Padur Aithal, et al.
Diabetes Research and Clinical Practice|August 15, 2024
Glycated haemoglobin is a major predictor of disease severity in patients with NAFLDSanto Colosimo, Hamish Miller, Dimitrios A Koutoukidis, et al.
JHEP Reports : Innovation in Hepatology|January 24, 2022
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevanceKatherine Johnson, Peter J Leary, Olivier Govaere, et al.
Alimentary Pharmacology & Therapeutics|April 17, 2020
Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolomeAhmad Moolla, Jasper de Boer, David Pavlov, et al.
Canadian Liver Journal|August 22, 2022
Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)Giada Sebastiani, Keyur Patel, Vlad Ratziu, et al.
Pageof 4